Home » Newsletters » BioWorld Science

BioWorld Science

May 3, 2022

View Archived Issues

OQL-051 shows prophylactic efficacy in models of chemotherapy-induced diarrhea

New EGFR inhibitors discovered at the Dana-Farber Cancer Institute

Storm Therapeutics identifies new METTL3 inhibitors

GlaxoSmithKline synthesizes new MRGPRX2 antagonists

Lilly patents dopamine D1 receptor positive allosteric modulators

Serine/threonine-protein kinase Pim-1 inhibitors identified at Japan Tobacco

Allogeneic colorectal cancer vaccine active against anti-PD-1-resistant colon cancer

S trimer-engaging multivalent protein neutralizes SARS-CoV-2 variants and protects mice

Identification of human MAb that broadly neutralizes sarbecoviruses unveils a crucial CDRH3 motif

Hemispherian closes seed funding to advance preclinical pipeline for cancer

Gilead and Dragonfly collaborate to advance NK cell engager-based immunotherapies

ProfoundBio antibody-drug conjugate PRO-1102 shows potency in vitro and in vivo

Ring Therapeutics describes in vitro system enabling human anellovirus production

Novel TRPC5 inhibitors show potential for the treatment of CKD

Tripartite interactions between nervous system, immune cells and plaques drive atherosclerosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...